Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy by Patrice Desmeules et al.
Desmeules et al. Diagnostic Pathology  (2015) 10:67 
DOI 10.1186/s13000-015-0294-0RESEARCH Open AccessComparison of digital image analysis and
visual scoring of KI-67 in prostate cancer
prognosis after prostatectomy
Patrice Desmeules3,5, Hélène Hovington1,3, Molière Nguilé-Makao1,3, Caroline Léger1,3, André Caron2,4,
Louis Lacombe1,3, Yves Fradet1,3, Bernard Têtu3,5 and Vincent Fradet1,3,6*Abstract
Background: The tumor proliferative index marker Ki-67 was shown to be associated with clinically significant
outcomes in prostate cancer, but its clinical application has limitations due to lack of uniformity and consistency in
quantification. Our objective was to compare the measurements obtained with digital image analysis (DIA) versus
virtual microscopy (visual scoring (VS)).
Methods: To do so, we compared the measurement distributions of each technique and their ability to predict
clinically useful endpoints. A tissue microarray series from a cohort of 225 men who underwent radical
prostatectomy was immunostained for Ki-67. The percentage of Ki-67 positive nuclei in malignant cells was
assessed both by VS and DIA, and a H–score was calculated. The distribution and predictive ability of these scoring
methods to predict biochemical recurrence (BCR) and death from prostate cancer (DPCa) were compared using
Mann–Whitney test and C-index.
Results: The measurements obtained with VS were similar to the DIA measurements (p = 0.73) but dissimilar to the
H-score (p < 0.001). Cox regression models showed that Ki-67 was associated with BCR (HR 1.46, 95 % CI 1.10-1.94)
and DPCa (HR 1.26, 95 % CI 1.06-1.50). C-indexes revealed that Ki-67 was a better predictor of DPCa (0.803, 0.8059
and 0.789; VS, DIA and H-score, respectively) than of BCR (0.625, 0.632 and 0.604; VS, DIA and H-score, respectively).
Conclusion: The measurement distributions and the predictive abilities of VS and DIA were similar and presented
the same predictive behaviour in our cohort, supporting the role of Ki-67 proliferative index as an important
prognostic factor of BCR and DPCa in prostate cancer post RP.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/6656878501536663
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Prostate cancer (PCa) is a major health problem, being
the most frequent cancer in men and a leading cause of
cancer-related death in North America [1]. Despite an
increase in the ability to detect cancer, the clinical be-
havior of prostate cancer remains hard to predict and
ranges from indolent course to aggressive evolution with* Correspondence: vincent.fradet@fmed.ulaval.ca
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creativecommons.org/publicdomain/zero/1.0/metastasis and death. Gleason score, tumor stage and
pre-operative PSA are the only current prognostic fac-
tors available, and are used, alone or in combination, to
predict the evolution of this disease [2, 3]. Nonetheless,
none of these factors has enough prognostic ability to
identify which patients should be additionally treated,
given their individual risk of biochemical recurrence or
death after radical prostatectomy.
In order to avoid over- or under-treatment, the ability
of several histologic measurements (including histo-
logical type, androgen receptor status [4], expression of
specific cancer markers such as p53, Ras oncogene, andss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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prognosis have been explored. The expression of the Ki-
67 antigen, a nuclear protein expressed during the G1, S,
G2 and M phases of the cell cycle but not during the
resting phase (G0) [8, 9], has emerged as the preferred
marker of tumor proliferation in different tissue types
[10–13], offering interesting predictive value in breast
cancer [14] and neuroendocrine digestive tumors [15].
Clinical studies have also shown the ability of this
marker to distinguish aggressive from non-aggressive PCa
in cohorts with different treatment modalities [16–26].
However, the integration of this analysis in the current
predictive arsenal to determine the appropriate treatment
strategy to adopt given the risk of progression remains a
challenge, mainly due to issues related to the reproducibil-
ity of measurement methods and application of a
threshold value.
Manual counting of a tumor proliferation index is
technically long and tedious and also subject to intra-
and inter-observer variability. In this context, digital
image analysis (DIA) offers a potential adjunct to con-
ventional visual scoring with the promise to increase re-
producibility, accuracy and rapidity of the quantification
process. Indeed, increasing reports of DIA reproducing
visual scoring at an acceptable level are found [27, 28].
However, it is unknown whether one method is superior
to the other to assess Ki-67 index, even in tumors with a
larger hindsight on DIA use such as breast cancer [29].
Such method still needs to be validated against trad-
itional visual assessment for a broader range of patients
and tissues.
Our objective was to compare the Ki-67 measure-
ments obtained with the DIA and the visual scoring
methods. To achieve this objective, we first compared
the measurement distributions of the two scoring
methods and then compared their ability to predict clin-
ically useful endpoints (biochemical failure and death by
prostate cancer) over time. We took advantage of a well-
constructed and characterized cohort of PCa patients
who underwent radical prostatectomy and benefited
from extended follow-up.
Methods
Patients and data collection
Patients included in this study were selected randomly
from a cohort of Caucasian men who were treated by
radical prostatectomy (RP) for localized prostate cancer
at L’Hôtel-Dieu de Québec (Québec city, Canada) be-
tween 1990 and 2002. Men were included if they had a
prostate adenocarcinoma of any stage treated with RP.
Patients who received neo-adjuvant androgen deprivation
therapy were excluded. All men provided informed writ-
ten consent to participate in this study. The Institutional
Ethical Research Committee approved the protocol.The patient’s medical files were reviewed to collect
clinical characteristics (age, stage, histology, Gleason
score, preoperative and follow-up serum PSA levels, sta-
tus at last follow-up). Clinical follow-up data were regu-
larly updated until June 2012 to document the
occurrence of progression or death after surgery. Clinical
follow-up was performed at least every year and in-
cluded PSA testing and physical examination. PSA re-
currence was defined as two consecutive PSA values of at
least 0.3 ng/mL, or one PSA value of at least 0.3 ng/mL
followed by androgen deprivation therapy or radiation
therapy, or PSA value less than 0.3 ng/mL but with an
androgen-deprivation therapy. Biochemical recurrence
(BCR) after radical prostatectomy was defined as the
period of time elapsed between the prostatectomy and the
first date of meeting the criteria of PSA recurrence. Pros-
tate cancer-specific mortality was defined as the interval
of time between the prostatectomy and death from pros-
tate cancer. For the purpose of statistical analysis, Gleason
scores were dichotomized (<7 vs ≥ 7) to group patients
with intermediate and less favorable prognostic. Patho-
logical stages were also grouped (pT2 vs pT3) to compare
between organ-confined versus extra-prostatic disease.TMA construction
For the preparation of tissue microarrays (TMA), one to
three paraffin blocks from each tumor was selected. Six
representative 0,6 mm tumor cores were taken and
placed 0,4 mm apart on a recipient paraffin block along
with appropriate alignment and staining controls using a
tissue arrayer (Beecher Instruments, Sun Prairie, WI,
USA). All primary tumor slices were examined and
graded by a pathologist (BT). Spots were selected from
haematoxylin and eosin slides to represent the proportion
of each Gleason patterns amongst dominant nodules and
include a tertiary pattern when present. Gleason scores
were also evaluated on TMA cores to ensure the represen-
tativeness of the sample with regard to the prostatectomy
specimen.
Immunohistochemistry and slide digitization
Sections five micron-thick were cut from the tissue array
blocks to perform immunohistochemistry. Sections were
deparafinized and heat-induced antigen retrieval was
performed by microwave pre-treatment in citrate
(0.01 M, pH 6.0). Endogenous peroxidase was blocked
by pre-incubation with 3 % hydrogen peroxide in
phosphate-buffered saline for 10 minutes. Sections were
then incubated with a monoclonal mouse anti-human
Ki-67 antibody (Clone MIB-1; Dako, Carpinteria, CA,
USA) at room temperature for 1 h at a 1/400 dilution.
Chromogenic detection was carried out using a
peroxidase-conjugated secondary antibody and DAB
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HRP (ID Labs, London, ON, Canada), and slides were
counter-stained with Harris’ hematoxylin. Positive con-
trols were slides of lympho-epithelial tissue. Phosphate
buffered saline was used instead of primary antibody in
negative controls.
Digital images of IHC-stained TMA slides were ob-
tained at 20× magnification using a slide scanner
(NanoZoomer 2.0-HT; Hamamatsu, Bridgewater, NJ,
USA) and visualized with the software ndpi.viewer
(ver1.2.25; Olympus). These images were used both for
the visual scoring and the digital image analysis.
Visual scoring
Ki-67 nuclear positivity was evaluated on digital images
by two independent observers (PD, HH) blinded to the
clinical data. The total number of Ki-67 positive tumor
nuclei was counted in malignant cells on each individual
TMA spot, regardless of the intensity of immunostaining
or the Gleason score. This count was reported on the
total number of malignant cells, calculated by using a
100-cell template moved over the whole tissue core. A
TMA spot was rejected when neoplastic glands covered
less than 30 % of the tissue. Moreover, a minimum num-
ber of 500 tumor cells per patient was require to keep
the sample for analysis. The mean percentage of Ki-67
positive cells for each patient was calculated and used in
further analysis as the Ki-67 labeling index.
Digital image analysis
Automated-IHC measurements were performed using
Calopix software (developed by TRIBVN [Chatillon,
France] and distributed by Agfa Healthcare [Toronto,
ON, Canada]). For the purpose of tissue recognition and
segmentation, the Ilastik 5.0 Interactive Learning and
Segmentation Toolkit within Calopix was used to create
a tissue mask and conserve only the malignant epithelial
component for analysis (see Additional file 1: Figure S1).
Then, the Calopix «immuno-object» software was ap-
plied to each segmentation result. The algorithm used
allows recognition of individual nuclei («objects») by
isolating brown (DAB stained) and blue (hematoxilin
counter-stained) nuclei, and report their numbers.
Within the algorithm, immunostaining is divided in in-
tensity categories (0 = none, 1 = weak, 2 =moderate, 3 =
strong), for which thresholds are set on visual appreci-
ation. Segmentation and quantification algorithms were
performed at 10× resolution, and all the results were
reviewed visually. When the tissue segmentation was
judged unsatisfactory (poor isolation of tumor glands), a
gross manual segmentation was done before re-launching
both Ilastik and immuno-object algorithms successively.
For each tissue core, the total number of objects detected
(i.e. tumor cell nuclei), the percent of immunostainedobjects in each of the four staining intensity categories
and the global percentage of immunostained objects were
computed. Those data were used to calculate a mean H-
score for each patient [30]. This compounded score is ob-
tained when the percentage of immunostained objects in
each intensity class is multiplied by the class’ category
value (0, 1, 2 or 3). The results are then added, with a
maximum value of 300.
Statistical analysis
First, Mann–Whitney-Wilcoxon tests were used to com-
pare the distribution of the mean number of Ki-67 posi-
tive cells per patient obtained with the visual and
automated methods. Second, Cox regression models
were used to estimate the effect of the Ki-67 labeling
index on the BCR or DPCa after RP according to the
measurements obtained with the two methods. PSA,
Gleason score and age were used as the adjustment co-
variates in multivariable analyses. In addition, we created
a high-risk predictor by identifying patients who had at
least one high-risk feature: high pathological stage (pT3),
nodal involvement and presence of positive margins
(pT3N +M+). Third, we built ROC curves, assessed the
AUC at the 12.5th year after the RP and estimated the C-
index over 12.5 years of follow-up after the RP. The C-
index is used to assess the prediction accuracy of three
measures of Ki-67 over time on the occurrence of BCR
and DPCa. The choice of this date (12.5 years) is justi-
fied by the fact that after this time, the prediction accur-
acy is confounded by naturally occurring death from
other causes. The statistical analyses were conducted
using R-software (Version R.3.0.2; Vienna, Austria) using
a two-sided alpha value of 0.05 to declare statistical
significance.
Results
Population and clinicopathological characteristics
Among the 251 eligible patients, the Ki-67 labeling index
could be evaluated in 225 patients by visual and digital as-
sessment. The remaining 26 patients were either missing
the visual or digital assessment because of inadequate
staining or technical issues. Patients’ characteristics are de-
tailed in Table 1. Stage pT3 disease was noted in 68 % of
patients and Gleason score ≥ 7 in 59.1 %. The mean age at
diagnosis was 63.2 years (SD: 6.10). The mean follow-up
duration until BCR and DPCa was 6.8 years (SD: 4.50)
and 10.6 years (SD: 3.06), respectively. During this time,
106 (47.1 %) patients experienced BCR, 44 (19.5 %) pa-
tients died, of which 10 (4.4 %) died of prostate cancer.
Immunohistochemistry
Ki-67 exhibited the expected nuclear staining and was
globally expressed at a low level throughout tumor cells,
and with considerable tissue heterogeneity. Using visual
Table 1 Baseline characteristics of study subjects
Characteristics Patients (n = 225)
Age (years), mean (SD) 63.2 (6.1)
Pre-op PSA (ng/mL), mean (SD) 12.8 (15.5)















Margin status, n (%)
0 (negative) 71 (31.6)
1 (positive) 154 (68.4)
Nodal status, n (%)
N0 186 (82.7)
N1 39 (17.3)




Biochemical recurrence, n (%)
No 119 (52.9)
Yes 106 (47.1)
Death by prostate cancer, n (%)
No 215 (95.6))
Yes 10 (4.4)
Death by other causes, n (%)
No 191 (84.9))
Yes 34 (15.1)
Death – all causes, n (%)
No 181 (80.4)
Yes 44 (19.6)
Time to BCR (years), mean (SD) 6.8 (4.5)
Time to DPCa (years), mean (SD) 10.6 (3.1)
DIA: digital image analysis; PSA: prostate-specific antigen; BCR: biochemical
recurrence; DPCa: Death by prostate cancer; SD: standard deviation; NA: non
available; N+: nodal involvement; M+: positive margins
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Ki-67 nuclear labeling was 2.23 (SD: 1.98) with a me-
dian of 1.61 (IQR: 0.71-3.23). With DIA, the mean Ki-
67 percentage was 2.05 (SD: 1.74) with a median of
1.48 (IQR: 0.86-2.83). Additional file 1: Figure S1 shows
an example of the tissue mask and the result of the ana-
lysis performed with DIA. Overall, due to tissue hetero-
geneity and complexity, poor discrimination of tumor
glands from high-grade PIN and in some case, the stro-
mal component, manual correction of segmentation
and/or analysis algorithm was performed on 38.1 % of
the tissue cores.
Comparison between visual assessment and DIA
A comparison of measurements was made between the
visual assessment of Ki-67 and the DIA. In Fig. 1, the
black dots represent the comparison between the visual
measures versus the global DIA measures, showing no
significant difference between the two methods (p =
0.73). In contrast, a significant difference was observed
between the weighted DIA measurements (H-Score) and
the visual assessments (p ≤ 0.001; blue dots).
Association between Ki-67 labeling index and
biochemical recurrence
As most studies published on the association between
Ki-67 and BCR used a binary model for Ki-67, we deter-
mined if this association was reproducible in our cohort.
In Additional file 5: Table S1, we first verified theFig. 1 Comparison of measurements methods. Ki-67 measures
obtained with digital image analysis (DIA) versus visual scoring
(black dots), and weighted DIA (H-score) versus visual scoring
(blue dots) were compared using a Mann–Whitney-Wilcoxon test.
Visual: visual scoring, Dig: DIA and Dig*: DIA compounded
measures of Ki-67 labeling index according to staining
intensity (H-score)
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demonstrated that the covariates used in our model
(continuous or binary Ki-67 labeling index, PSA score,
Gleason score, nodal involvement and presence of
margin involvement in high stage tumors [high-risk
score: pT3N +M+] and age) all verified the
proportionality assumption. In Additional file 2: Figure
S2, we demonstrate that age, Gleason score and PSA
are log-linear. Cox model with a binary Ki-67 (cutoff =
1.7 %) showed that both the non-adjusted and adjusted
models were significantly associated with BCR (HR 1.7,
95 % CI 1.53–2.52 and HR 1.87, 95 % CI 1.25 – 2.81,
respectively), thus successfully reproducing previously
published observations.
We then set up to determine if Ki-67 used as a con-
tinuous variable could also be predictive of BCR. For this
procedure, we verified if Ki-67 staining was log-linear.
As shown in Additional file 3: Figure S3, log-linearity for
Ki-67 was only obtained with a square-root transform-
ation. Table 2 shows that the association between Ki-67
and BCR is not significant in the univariate Cox model
(HR 1.29, 95 % CI 0.97 – 1.73), but becomes significant
after incorporating the adjustment covariates (HR 1.46,
95 % CI 1.10-1.94). Furthermore, we noted that the vari-
ance of the estimates of the continuous model of Ki-67
is smaller than the binary model, both for the univariateTable 2 Ki-67 as a predictor of clinically significant outcomes
Outcome: Biochemical recurrence
HR 95 % CI p-value
Univariate model
Ki-67*,& 1.29 0.97-1.73 0.019
Multivariate model
Ki-67*& 1.46 1.10-1.94 0.009
PSA (μg/L) 1.02 1.01-1.03 <0.001
Gleason Score& 1.09 0.94-1.26 0.25
pT3N +M+ 1.47 1.17-1.84 <0.001
Age (years) 0.96 0.93-0.99 0.02
Outcome: Death from prostate cancer
HR 95 % CI p-value
Univariate model
Ki-67& 1.19 1.01-1.41 0.040
Multivariate model
Ki-67& 1.26 1.06-150 0.010
PSA (μg/L) 1.01 0.98-1.04 0.577
Gleason Score& 1.30 0.79-2.14 0.293
pT3N +M+ 3.49 1.19-10.23 0.022
Age (years) 0.97 0.86-1.08 0.554
Ki-67*: The square root of Ki-67; PSA: Prostate-specific antigen; HR: Hazard
ratio; CI: Confidence interval
&Ki-67 was assessed as a continuous variable. Gleason score was dichotomized
to <7 vs ≥ 7(var = 0.147 versus 0.199, respectively) and multivariate
(var = 0.145 versus 0.206, respectively) analysis.
Nonetheless, Fig. 2 shows that Ki-67 non-adjusted (A)
or adjusted (C), used as a continuous variable is not a
good predictor of BCR at the 12.5th year after RP. The
conclusion holds even when we evaluate its ability to
predict BCR over 12.5 years. Indeed the C-indexes of the
adjusted model (D) of the visual scoring, DIA and
weighted DIA (H-score) computed over 12.5 years are,
respectively, 0.549, 0.650 and 0.640, these prediction
probabilities not being significantly different from
chance alone.
Association between Ki-67 labeling index and death by
prostate cancer
In our second type of models, we considered the associ-
ation between Ki-67 and death by prostate cancer. Since
the continuous Ki-67 modeling was superior to the bin-
ary model, we performed the following tests only with
the continuous modeling. In this model, we also used
Ki-67, PSA score, Gleason score, high-risk score (pT3N +
M+) and age as adjustment covariates. For this model, all
those covariates verified the proportionality (Additional
file 5: Table S1) and log-linearity assumptions (Additional
file 4: Figure S4). The association between Ki-67 and
DPCa was positive in the univariate (HR 1.19, 95 % CI
1.01 – 1.41) and multivariate (HR 1.26, 95 % CI 1.06-1.50)
models (Table 3). The ability of the adjusted Ki-67 is bet-
ter than the non-adjusted Ki-67 to predict DPCa at the
end of the follow-up period (i.e. 12.5 years) (Fig. 3C vs
Fig. 3A). Furthermore, we also observed that the ability of
the non-adjusted measure of Ki-67 to predict DPCa over
time (Fig. 3B) is weak, as the C-indexes computed over
12.5 years with the measures obtained by visual scoring,
DIA and weighted DIA, are only 0.632, 0.625 and 0.604,
respectively. On the other hand, the ability of the adjusted
Ki-67 to predict DPCa is good (Fig. 3D), with C-indexes
(computed over 12.5 years) for the measurements done by
visual scoring, DIA and weighted DIA of 0.803, 0.805 and
0.789, respectively. The mean values of C-index obtained
by the bootstrap method are depicted in Table 3. We
noted that the three measurements in adjusted models are
good predictors of the DPCa; however, only the measure-
ment distributions of the VS and DIA are significantly
similar (Fig. 1) and they have the same C-index value.
Discussion
Uncontrolled proliferation is a hallmark of malignancy
and the measurement of Ki-67 antigen by immunohisto-
chemistry is the most widely performed assessment of
the proliferative potential of tumors. Several studies are
supporting a role for this marker in the prediction of
clinically significant outcomes in prostate cancer, such
as biochemical recurrence and death, but it is not
Fig. 2 Prediction accuracy of Cox regression model (outcome: biochemical recurrence). The graphs (a) and (c) represent the ROC curve at the
12.5th year after radical prostatectomy for the non-adjusted and adjusted model, respectively. The graphs (b) and (d) depict the C-index for the
non-adjusted and adjusted model, respectively assessed on 12.5 years after radial prostatectomy. The red curve represents the chance while the
black, blue and green line represents the measures obtained with DIA, H-score and the visual scoring, respectively. TP = true positive;
FP = false positive
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histopathological factors, clinical adoption is challenged
by the weak reproducibility in measurement methods,
poor standardization of assays and the need for clinical
agreement on an appropriate measurement method, as
noted by a group evaluating Ki-67 measurement in
breast cancer [29]. Variability between pathologists’ as-
sessments of Ki-67 index was reported to be high,
reflecting the differences inherent to subjective countingTable 3 Confidence intervals of the C-indices for the
multivariate Cox regression models predicting death
by prostate cancer*
Mean 95 % CI
C-index VS 0.850 0.728-0.959
C-index DIA 0.850 0.734-0.960
C-index H-score 0.834 0.724-0.950
CI: Confidence interval; VS: visual scoring
DIA: digital image analysis
*The CI were constructed using the bootstrap method
(300 iterations)in terms of positivity threshold interpretation, field selec-
tion as well as other factors [31]. In the absence of har-
monized methodology, the integration of Ki-67 in a
prognostic composite index is very difficult.
In this TMA study of PCa patients who underwent RP,
we measured the expression level of Ki-67 in 225 pa-
tients by both DIA and visual scoring. With the DIA
method we used, the mean labeling index (2.05 %) was
similar to the one measured by visual scoring (2.23 %).
Nonetheless, since similarities in the labeling index mea-
surements between the two methods does not guarantee
similar associations with clinical outcomes, we compared
them based on time-dependent AUC (C-index) and
show that both methods performed similarly to predict
BCR and DPCa. Not only was the DIA able to reproduce
the relationship with clinico-pathological outcomes ob-
tained by visual scoring of Ki-67 index, it also had a
similar pattern of prediction. Indeed, the C-index indi-
cates that both methods allow one to discriminate be-
tween those who will die from their prostate cancer
from those who won’t, even when we take into account
Fig. 3 Prediction accuracy of Cox regression model (outcome: death by prostate cancer). The graphs (a) and (c) represent the ROC curve at the
12.5th year after radical prostatectomy for the non-adjusted and adjusted model, respectively. The graphs (b) and (d) depict the C-index for
non-adjusted and adjusted models, respectively assessed on 12.5 years after radial prostatectomy. The red curve represents the chance, while
the black, blue and green line represents the measures obtained with DIA, H-score and the visual scoring, respectively. TP = true positive;
FP = false positive
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as low as 19 %. Therefore, our results suggest that DIA
might be a reliable method to assess proliferation index
in patients affected with high risk PCa.
We observed a weak independent predictive role of
Ki-67 positivity on BCR. These results are consistent
with prior studies that have shown Ki-67 labeling index
to be associated with BCR in prostate cancer patients
treated with radical prostatectomy [23, 32–34], as re-
cently highlighted in a large multicenter study [35]. The
association with BCR was also observed using Ki-67 in-
tegrated in a three-marker composite index of prolifera-
tion [36], although it could be restricted to tumors with
ERG- status [37]. One strength of the current study is
that this association was observed for both a dichotom-
ous (≤1.7 % or >1.7 %) as well as for a continuous meas-
urement of Ki-67. The low cut-off point obtained could
be related to TMA sampling or the sharp tissue segmen-
tation we aimed at and the fact that we performed an
exhaustive count of tumor cells rather than a «hot spot»
approach, which might be factors preventing theoverestimation of the proliferative index. We are
confident that the data generated are valid because they
were confirmed by two modalities of quantification (vis-
ual scoring and DIA).
In our cohort, Ki-67 was a much more potent pre-
dictor of DPCa than of BCR. When looking only at co-
horts of patients undergoing radical prostatectomy, the
association between Ki-67 and DPCa has been shown in
some [16, 22] but not all [38] studies. Many studies con-
sidered only biochemical failure and did not assess
DPCa, while others included patient populations with
heterogeneous treatments or measured proliferative
index in nodal metastases instead of primary tumors
[39–41]. This is in contrast with the strong relationship
between death and Ki-67 proliferative index observed in
radiotherapy or watchful waiting cohorts (reviewed in
Fisher 2013 [42]). Our own study confirmed that Ki-67
expression is positively associated with DPCa in a cohort
of closely followed RP patients. Interestingly, when we
considered the association between Ki-67 and death
from other causes than prostate cancer, we found a
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% CI 0.13-0.77; p = 0.04). This observation suggests that
Ki-67’s role in predicting death from prostate cancer
might be very specific.
There are a growing number of reports of automated
Ki-67 quantification data generated with software algo-
rithms and of agreement with visual counts in several
tissue and tumor types [43–46]. When different tech-
niques of measurement of Ki-67 were compared in
breast cancer, DIA was found to be even prognostically
stronger than visual counting [31]. The use of DIA tech-
nique to quantify Ki-67 was also used successfully in
PCa [24–26, 35, 47], but few studies have directly com-
pared the two modalities. In one radiation therapy co-
hort measuring the proliferative index on prostate
biopsies samples, there was a stronger correlation be-
tween clinical outcomes and visual scoring than with
DIA [48]. This contrast with our results might reflect
differences in sampling (biopsy vs TMAs), analysis (di-
chotomous vs continuous) and DIA methods. Our study
also shows that the assessment of Ki-67 as a continuous
variable is better than as a dichotomous variable because
the HR estimates are better (the variance is smaller than
in the dichotomous model), supporting the notion that
capacity of acquiring continuous data is one advantage
of the DIA technology. Finally, the algorithm used for
our DIA measurements provided direct nuclei count
with fractionation of staining in intensity classes. It
allowed us to assess if a weighted H-score would perform
better than raw percentage. Our results suggest that subtle
intensity variations in Ki-67 staining, as detected with DIA
and transposed into a H-score, adds no additional clinically
useful information in prostate cancer.
The DIA system we used was successfully applied in
morphologically complex tumors such as ovarian carcin-
omas [49], but resulted in high number of manual ad-
justments for tissue segmentation in our cohort of
prostate carcinoma. This result reflects the subtleties in
morphologic differences between malignant and benign
glands in prostate cancer, as we aimed to perform sharp
neoplastic gland segmentation, and the difficulty of DIA
modalities to discriminate them without counter verifi-
cation. It also underscores that an accurate assessment
of tumor cells is mandatory when faced with a tumor
with a low mean value of proliferative cells, since
small variations may have a larger impact on data in-
terpretation. Present estimations of the time needed
for a pathologist to make a careful objective count is
approximately 20 minutes, similar to the estimated
time needed to perform DIA [31], especially if manual
correction of tissue segmentation is required. It is rea-
sonable to expect that with experience and availability
of new softwares, quantitative DIA will be easier to
apply and will lead to more constant and reproducibleresults, as the machine is not subject to fatigue nor to
inter and intra observer variability. In addition, it re-
mains that pre-analytical aspects inherent to tissue
processing and immunohistochemistry techniques are
also critical to optimize the performance of DIA [29].
There are potential limitations to our study that merit
consideration. First, because of the relatively small num-
ber of patients, we could not perform a validation step.
Therefore, the results obtained with our cohort of 225
patients will need to be validated in an independent co-
hort of patients. Second, the relatively high rate of man-
ual adjustments of segmentation with the DIA technique
certainly contributed to increase the precision of our
findings but increased the technical burden of our ap-
proach. More methodological work is justified and
needed to facilitate the application of our approach to
the clinic. We also observed a low level of DPCa in our
cohort. In order to compensate for this, an analysis tak-
ing the occurrence of positive margins and nodal in-
volvement (high risk features) as a surrogate marker of
dismal evolution was performed and reproduced our re-
sults (multivariate model; HR 3.49, 95 % CI 1.19-10.23;
see Table 2). In addition, most of the patients in our co-
hort had a high stage (T3) tumor, and our results
should be validated in a cohort with a more evenly dis-
tributed pathological stage to ensure that our findings
are generalizable to lower stage prostate cancer pa-
tients. However, 31 % of such low-stage patients were
included in our cohort and our analysis account for the
stage effect, rendering confounding by stage unlikely.
Finally, the use of TMAs rather than whole tissue sec-
tions might limit the transposition of our results to
prostatectomy specimens. Tissue microarrays offer a
tissue sampling independent of biomarker’s expression,
thus reducing the opportunity for selection bias (e.g. of
counting areas) and allows for a reduction in the num-
ber of immunohistochemistry runs, conferring more
homogenous conditions for marker quantification. For
Ki-67 measurements in PCa, specifically, it was sug-
gested that as few as three TMA spots were sufficient
to predict PSA failure [50]. However, since prostatec-
tomy whole tissue sections are more convenient for dir-
ect clinical use, a validation of our results with such
specimens should be done.Conclusions
In summary, our results show that the digital image ana-
lysis method we developed is comparable to visual scor-
ing for quantifying Ki-67 expression in prostate cancer
and predicting important clinical outcomes. Also, they
show that the use of Ki-67 as a continuous variable is
more reliable than using the traditional dichotomous
approach. With improved standardization, DIA could
Desmeules et al. Diagnostic Pathology  (2015) 10:67 Page 9 of 10become a clinically useful mean of measuring Ki-67, a
proliferating marker associated with risk of BCR and
DPCa in prostate cancer patients.
Additional files
Additional file 1: Figure S1. A. Representative prostate carcinoma TMA
spot with Ki-67 immunostaining. B. The corresponding result of
automated tissue segmentation and analysis of nuclei staining by digital
image analysis is shown; Pink = tissue mask; circles: blue = no staining
detected; yellow, orange and red = light, moderated and high levels of
intensity recognized by the software, respectively. (TIFF 2931 kb)
Additional file 2: Figure S2. Log-linearity test for the covariates used in
the Cox regression model for biochemical recurrence. The log-linearity of
the four covariates, i.e. Ki-67 (A), PSA (B), Gleason score (C) and age (D)
was assessed. The red line in each graph represents the perfect log-linearity
while the black line shows the behavior of each variable. Only Ki-67 deviates
from log-linearity.
Additional file 3: Figure S3. Transformation of Ki-67 to reach log-linearity
in the Cox regression model for biochemical recurrence. As Ki-67 was
shown not to be log-linear, a square root transformation was performed
(Ki-67*). The red line in each graph represents the perfect log-linearity while
the black line shows the behavior of each variable. As shown in panel A,
Ki67 respected the log-linearity assumption of the Cox regression model for
biochemical recurrence after a square root transformation.
Additional file 4: Figure S4. Log-linearity test for the covariates used in
the Cox regression model for death by prostate cancer. The log-linearity
of the four covariates, i.e. Ki-67 (A), PSA (B), Gleason score (C) and age (D)
was assessed. The red line represents the perfect log-linearity while the
black line shows the behavior of each variable.
Additional file 5 Table S1: Verification of the proportionality
assumptions for the covariates used in the Cox regression models.
Verification of the proportionality assumptions for the covariates used in
the Cox regression model for biochemical recurrence and death by
prostate cancer. All covariates verified the assumption.
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